Sarcoma

Sarcoma Research Reagents

Sarcomas encompass over 100 histological subtypes of mesenchymal origin, broadly classified into soft tissue sarcomas (STS) and bone sarcomas. Common subtypes include liposarcoma (well-differentiated/dedifferentiated, myxoid/round cell), leiomyosarcoma, undifferentiated pleomorphic sarcoma, gastrointestinal stromal tumor (GIST), and osteosarcoma. Subtype-specific systemic therapies include imatinib for KIT/PDGFRA-mutant GIST, trabectedin for L-sarcomas, and emerging adoptive T cell therapy targeting NY-ESO-1 in synovial sarcoma.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Sarcoma Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in sarcoma. MDM2/CDK4 amplification in liposarcoma, KIT/DOG1 signaling in GIST, and NY-ESO-1 expression for immunotherapy. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key sarcoma research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

MDM2 / CDK4 — MDM2 amplification and CDK4 co-amplification are hallmarks of well-differentiated and dedifferentiated liposarcoma, the most common STS subtype. Anti-MDM2 and anti-CDK4 antibodies enable IHC-based diagnostic confirmation (distinguishing from benign lipomatous tumors), FISH surrogate assessment, and CDK4/6 inhibitor sensitivity research.
→ Browse MDM2 antibodies & proteins

KIT (CD117) / DOG1 — KIT and DOG1 are the canonical diagnostic markers for gastrointestinal stromal tumors (GIST). Anti-KIT and anti-DOG1 antibodies support diagnostic IHC, imatinib resistance mutation studies, and research into KIT-independent GIST driven by PDGFRA D842V or SDH-deficient biology.
→ Browse KIT antibodies & proteins

NY-ESO-1 (CTAG1B) — NY-ESO-1 is a cancer-testis antigen expressed in >80% of synovial sarcomas and ~30% of myxoid liposarcomas. Anti-NY-ESO-1 antibodies enable expression profiling for adoptive T cell therapy eligibility, vaccine development, and engineered TCR-T cell therapeutic research.
→ Browse NY-ESO-1 antibodies & proteins

References

1. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-480. DOI

2. D’Angelo SP, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1-specific T cells in synovial sarcoma. Cancer Discov. 2018;8(8):944-957. DOI

3. The Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950-965. DOI

4. Gronchi A, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines. Ann Oncol. 2021;32(11):1348-1365. DOI

Recombinant Proteins

Antibodies

Assay Kits

Sarcoma

Sarcoma Research Reagents

Get a free quote